Results 21 to 30 of about 144,216 (270)

Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy. [PDF]

open access: yes, 2017
We present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented with left lower extremity edema, erythema, and pain.
Adashek, Jacob   +6 more
core   +5 more sources

Warfarin Sodium Stability in Oral Formulations

open access: yesMolecules, 2021
Warfarin sodium is a low-dose pharmaceutical blood thinner that exists in two forms: the clathrate form and the amorphous form. In commercially available warfarin sodium oral suspension, the active pharmaceutical ingredient (API) is added in the ...
Evangelia Dimitrokalli   +5 more
doaj   +1 more source

Clinical application of high throughput molecular screening techniques for pharmacogenomics. [PDF]

open access: yes, 2011
Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples.
Schrijver, Iris, Wiita, Arun P
core   +1 more source

Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interaction

open access: yesScientific Reports, 2017
Recent global deregulation of ginseng as the table food raises our concern about the possible ginseng-warfarin interaction that could be life-threatening to patients who take warfarin for preventing fatal strokes and thromboembolism while using ginseng ...
Haiyan Dong   +8 more
doaj   +1 more source

The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study. [PDF]

open access: yesPLoS ONE, 2016
Warfarin oral anticoagulant therapy (OAT) requires regular and frequent drug adjustment monitored by INR. Interindividual variability, drug and diet interferences, and genetics (VKORC1 and CYP2C9) make the maintenance/reaching of stable INR a not so easy
Donato Gemmati   +11 more
doaj   +1 more source

Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

open access: yesAngewandte Chemie, EarlyView.
Understanding stereoselective biotransformations has implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in metabolite and API synthesis. ABSTRACT Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different ...
Grace A. Okunlola, Godwin A. Aleku
wiley   +2 more sources

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

open access: yes, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group   +23 more
core   +1 more source

One Rare Warfarin Resistance Case and Possible Mechanism Exploration

open access: yesPharmacogenomics and Personalized Medicine, 2023
Li Zhao,1 Zhenguo Zhai,2 Pengmei Li1 1Pharmacy Department, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 2Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, People’s Republic of ...
Zhao L, Zhai Z, Li P
doaj  

Warfarin reversal [PDF]

open access: yesJournal of Clinical Pathology, 2004
Warfarin is the most commonly used oral anticoagulant in the UK. It is associated with few side effects apart from haemorrhage. The most appropriate way to reverse the anticoagulant effect of warfarin depends on the clinical circumstances. In serious bleeding, rapid reversal is required, whereas in minor bleeding or asymptomatic over anticoagulation, a
openaire   +2 more sources

Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]

open access: yes, 2016
BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core   +2 more sources

Home - About - Disclaimer - Privacy